207 related articles for article (PubMed ID: 22229849)
1. Targeted therapies and predictive markers in epithelial malignancies of the gastrointestinal tract.
McIntire M; Redston M
Arch Pathol Lab Med; 2012 May; 136(5):496-503. PubMed ID: 22229849
[TBL] [Abstract][Full Text] [Related]
2. Changing pathology with changing drugs: tumors of the gastrointestinal tract.
Cervera P; Fléjou JF
Pathobiology; 2011; 78(2):76-89. PubMed ID: 21677471
[TBL] [Abstract][Full Text] [Related]
3. Predictors of response to targeted therapies for gastrointestinal stromal tumors.
Marrari A; Wagner AJ; Hornick JL
Arch Pathol Lab Med; 2012 May; 136(5):483-9. PubMed ID: 22229850
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies in gastrointestinal cancers.
Bronte G; Cicero G; Cusenza S; Galvano A; Musso E; Rizzo S; Sortino G; Roselli M; Bazan V; Fiorentino E; Russo A
Expert Opin Biol Ther; 2013 Jun; 13(6):889-900. PubMed ID: 23441760
[TBL] [Abstract][Full Text] [Related]
5. The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC.
Hirsch FR
Oncogene; 2009 Aug; 28 Suppl 1():S1-3. PubMed ID: 19680291
[TBL] [Abstract][Full Text] [Related]
6. Predictive factors to targeted treatment in gastrointestinal carcinomas.
Silvestris N; Marech I; Brunetti AE; Azzariti A; Numico G; Cicero G; Delcuratolo S; De Luca R; Burz C; Lorusso V
Cancer Biomark; 2014; 14(2-3):151-62. PubMed ID: 24878816
[TBL] [Abstract][Full Text] [Related]
7. Predictors of response to targeted therapy in renal cell carcinoma.
Eisengart LJ; MacVicar GR; Yang XJ
Arch Pathol Lab Med; 2012 May; 136(5):490-5. PubMed ID: 22229848
[TBL] [Abstract][Full Text] [Related]
8. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
John T; Liu G; Tsao MS
Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
[TBL] [Abstract][Full Text] [Related]
9. Molecular predictors of response to chemotherapy in colorectal cancer.
Dienstmann R; Vilar E; Tabernero J
Cancer J; 2011; 17(2):114-26. PubMed ID: 21427555
[TBL] [Abstract][Full Text] [Related]
10. Progress in cancer chemotherapy with special stress on molecular-targeted therapy.
Saijo N
Jpn J Clin Oncol; 2010 Sep; 40(9):855-62. PubMed ID: 20651047
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics and pharmacogenomics: role of mutational analysis in anti-cancer targeted therapy.
Savonarola A; Palmirotta R; Guadagni F; Silvestris F
Pharmacogenomics J; 2012 Aug; 12(4):277-86. PubMed ID: 22760589
[TBL] [Abstract][Full Text] [Related]
12. Array-based pharmacogenomics of molecular-targeted therapies in oncology.
Sanoudou D; Mountzios G; Arvanitis DA; Pectasides D
Pharmacogenomics J; 2012 Jun; 12(3):185-96. PubMed ID: 22249357
[TBL] [Abstract][Full Text] [Related]
13. [Predictive and prognostic factors in the neoadjuvant/adjuvant therapy of gastrointestinal tumors: wishful thinking or reality?].
Vallböhmer D; Lenz HJ
Zentralbl Chir; 2006 Apr; 131(2):148-56. PubMed ID: 16612782
[TBL] [Abstract][Full Text] [Related]
14. Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies.
Stella GM; Luisetti M; Inghilleri S; Cemmi F; Scabini R; Zorzetto M; Pozzi E
Respir Med; 2012 Feb; 106(2):173-83. PubMed ID: 22104541
[TBL] [Abstract][Full Text] [Related]
15. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
Shigematsu H; Takahashi T; Nomura M; Majmudar K; Suzuki M; Lee H; Wistuba II; Fong KM; Toyooka S; Shimizu N; Fujisawa T; Minna JD; Gazdar AF
Cancer Res; 2005 Mar; 65(5):1642-6. PubMed ID: 15753357
[TBL] [Abstract][Full Text] [Related]
16. Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors.
Gilbert JA; Adhikari LJ; Lloyd RV; Rubin J; Haluska P; Carboni JM; Gottardis MM; Ames MM
Endocr Relat Cancer; 2010 Sep; 17(3):623-36. PubMed ID: 20385747
[TBL] [Abstract][Full Text] [Related]
17. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
Le Tourneau C; Vidal L; Siu LL
Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176
[TBL] [Abstract][Full Text] [Related]
18. EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors.
Sartori G; Cavazza A; Sgambato A; Marchioni A; Barbieri F; Longo L; Bavieri M; Murer B; Meschiari E; Tamberi S; Cadioli A; Luppi F; Migaldi M; Rossi G
Am J Clin Pathol; 2009 Apr; 131(4):478-89. PubMed ID: 19289583
[TBL] [Abstract][Full Text] [Related]
19. Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies.
Cappetta A; Lonardi S; Pastorelli D; Bergamo F; Lombardi G; Zagonel V
Crit Rev Oncol Hematol; 2012 Jan; 81(1):38-48. PubMed ID: 21256046
[TBL] [Abstract][Full Text] [Related]
20. Somatic alterations as the basis for resistance to targeted therapies.
Blair BG; Bardelli A; Park BH
J Pathol; 2014 Jan; 232(2):244-54. PubMed ID: 24114654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]